Navidea Biopharmaceuticals Inc (NAVB)

[LasNubes]

Yes. The company was obviously thrilled by the FDA decision although they were hoping for a more expanded label. They stressed that their indication for melanoma and breast is the majority of the market. They have a solid partner in Cardinal and will gear up sales and marketing. They split profits 50-50 with Cardinal.
They are excited about starting in Europe and their pipeline and further studies with other tumor types.
They are pushing forward with very clear goals and objectives.